In this Japanese multicenter study, high neo‐GPSs were associated with poor prognosis in patients with HCC who received Atez/Bev therapy, the combination therapy of an immune checkpoint inhibitor (Atez) and an antibody against vascular endothelial growth factor (Bev) that was developed as first‐choice therapy for patients with unresectable HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.